Evidence map›Paper›PMID 33908410›Full record

ArticleEar and hearing

Cochlear Synaptopathy due to Mutations in OTOF Gene May Result in Stable Mild Hearing Loss and Severe Impairment of Speech Perception.

Rosamaria Santarelli, Pietro Scimemi, Marco Costantini, María Domínguez-Ruiz, Montserrat Rodríguez-Ballesteros, Ignacio Del Castillo

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Ear and hearing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07778641 (Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07778641 not yet recruitingnot on this map

Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder

Typeobservational_patient_registrySponsorSohag UniversityRan2026 to 2027Enrolled30ConditionsAuditory Neuropathy Spectrum Disorder, Auditory NeuropathyArmsWhole exome sequencing.
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. FDA Approval of the Congenital OTOF Gene Therapy Otarmeni Reshapes the Future of Hearing Care.Journal of the Association for Research in Otolaryngology : JARO · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Rosamaria SantarelliDepartment of Neurosciences, University of Padua, Padua, Italy.
Pietro ScimemiDepartment of Neurosciences, University of Padua, Padua, Italy.
Marco CostantiniDepartment of Neurosciences, University of Padua, Padua, Italy.
María Domínguez-RuizServicio de Genética, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Montserrat Rodríguez-BallesterosServicio de Genética, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Ignacio Del CastilloServicio de Genética, Hospital Universitario Ramón y Cajal, Madrid, Spain.
University of Padua · ITCentre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red · ESHospital Universitario Ramón y Cajal · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCongenital profound hearing loss with preserved cochlear outer hair cell activity (otoacoustic emissions and cochlear microphonic) is the most common phenotype associated with mutations in the OTOF gene. The aim of this study was to investigate the pathophysiological mechanisms behind the auditory dysfunction in five patients (2 adults and 3 children) carrying biallelic mutations in OTOF, who showed an uncommon phenotype of mild hearing impairment associated with severe difficulties in speech perception and delay of language development.

designPatients underwent audiometric assessment with pure-tone and speech perception evaluation, and otoacoustic emissions and auditory brainstem response recording. Cochlear potentials were recorded in all subjects through transtympanic electrocochleography in response to clicks delivered in the free field from 120 to 60 dB peak equivalent SPL and were compared to recordings obtained from 20 normally hearing controls and from eight children with profound deafness due to mutations in the OTOF gene. Three patients out of five underwent unilateral cochlear implantation. Speech perception measures and electrically evoked auditory nerve potentials were obtained within 1 year of cochlear implant use.

resultsPathogenic mutations in the two alleles of OTOF were found in all five patients, and five novel mutations were identified. Hearing thresholds indicated mild hearing loss in four patients and moderate hearing loss in one. Distortion product otoacoustic emissions were recorded in all subjects, whereas auditory brainstem responses were absent in all but two patients, who showed a delayed wave V in one ear. In electrocochleography recordings, cochlear microphonics and summating potentials showed normal latency and peak amplitude, consistently with preservation of both outer and inner hair cell activity. In contrast, the neural compound action potential recorded in normally hearing controls was replaced by a prolonged, low-amplitude negative response. No differences in cochlear potentials were found between OTOF subjects showing mild or profound hearing loss. Electrical stimulation through the cochlear implant improved speech perception and restored synchronized auditory nerve responses in all cochlear implant recipients.

conclusionsThese findings indicate that disordered synchrony in auditory fiber activity underlies the impairment of speech perception in patients carrying biallelic mutations in OTOF gene who show a stable phenotype of mild hearing loss. Abnormal nerve synchrony with preservation of hearing sensitivity is consistent with selective impairment of vesicle replenishment at the ribbon synapses with relative preservation of synaptic exocytosis. Cochlear implants are effective in restoring speech perception and synchronous activation of the auditory pathway by directly stimulating auditory fibers.

Indexed as

Hearing LossMembrane ProteinsSpeech PerceptionAuditory ThresholdCochleaCochlear NerveEvoked Potentials, Auditory, Brain StemHumansMutationOtoacoustic Emissions, SpontaneousMembrane ProteinsOTOF protein, human

Identifiers

PMID33908410
PMCPMC9973442
OpenAlexW3158297300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.